198 related articles for article (PubMed ID: 1722166)
1. Steroid hormones and the pathogenesis of benign prostatic hyperplasia.
Griffiths K; Eaton CL; Harper ME; Peeling B; Davies P
Eur Urol; 1991; 20 Suppl 1():68-77. PubMed ID: 1722166
[TBL] [Abstract][Full Text] [Related]
2. [Benign prostatic hyperplasia--the outcome of age-induced alteration of androgen-estrogen balance?].
Weisser H; Krieg M
Urologe A; 1997 Jan; 36(1):3-9. PubMed ID: 9123678
[TBL] [Abstract][Full Text] [Related]
3. The role of dihydrotestosterone in benign prostatic hyperplasia.
Carson C; Rittmaster R
Urology; 2003 Apr; 61(4 Suppl 1):2-7. PubMed ID: 12657354
[TBL] [Abstract][Full Text] [Related]
4. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
Habib FK; Ross M; Tate R; Chisholm GD
Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
[TBL] [Abstract][Full Text] [Related]
5. Androgens and estrogens: their interaction with stroma and epithelium of human benign prostatic hyperplasia and normal prostate.
Krieg M; Bartsch W; Thomsen M; Voigt KD
J Steroid Biochem; 1983 Jul; 19(1A):155-61. PubMed ID: 6193338
[TBL] [Abstract][Full Text] [Related]
6. Changes in dihydrotestosterone metabolism and the development of benign prostatic hyperplasia in the aging beagle.
Isaacs JT
J Steroid Biochem; 1983 Jun; 18(6):749-57. PubMed ID: 6191128
[TBL] [Abstract][Full Text] [Related]
7. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
[TBL] [Abstract][Full Text] [Related]
8. 5alpha-reductase activity in the prostate.
Steers WD
Urology; 2001 Dec; 58(6 Suppl 1):17-24; discussion 24. PubMed ID: 11750244
[TBL] [Abstract][Full Text] [Related]
9. Oxytocin and prostatic function.
Nicholson HD; Jenkin L
Adv Exp Med Biol; 1995; 395():529-38. PubMed ID: 8714010
[TBL] [Abstract][Full Text] [Related]
10. Clinical and experimental studies of benign prostatic hyperplasia.
Coffey DS; Walsh PC
Urol Clin North Am; 1990 Aug; 17(3):461-75. PubMed ID: 1695775
[TBL] [Abstract][Full Text] [Related]
11. Cynomorium songaricum Rupr demonstrates phytoestrogenic or phytoandrogenic like activities that attenuates benign prostatic hyperplasia via regulating steroid 5-α-reductase.
Tao R; Miao L; Yu X; Orgah JO; Barnabas O; Chang Y; Liu E; Fan G; Gao X
J Ethnopharmacol; 2019 May; 235():65-74. PubMed ID: 30708032
[TBL] [Abstract][Full Text] [Related]
12. Regional variations of insulin-like growth factor I (IGF-I), IGF-II, and receptor type I in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens.
Monti S; Di Silverio F; Iraci R; Martini C; Lanzara S; Falasca P; Poggi M; Stigliano A; Sciarra F; Toscano V
J Clin Endocrinol Metab; 2001 Apr; 86(4):1700-6. PubMed ID: 11297606
[TBL] [Abstract][Full Text] [Related]
13. Benign prostatic hyperplasia: pathogenesis and medical therapy.
Geller J
J Am Geriatr Soc; 1991 Dec; 39(12):1208-16. PubMed ID: 1720438
[TBL] [Abstract][Full Text] [Related]
14. Changes in dihydrotestosterone metabolism associated with the development of canine benign prostatic hyperplasia.
Isaacs JT; Coffey DS
Endocrinology; 1981 Feb; 108(2):445-53. PubMed ID: 6161001
[TBL] [Abstract][Full Text] [Related]
15. Estrogen and androgen signaling in the pathogenesis of BPH.
Ho CK; Habib FK
Nat Rev Urol; 2011 Jan; 8(1):29-41. PubMed ID: 21228820
[TBL] [Abstract][Full Text] [Related]
16. Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content.
Forti G; Salerno R; Moneti G; Zoppi S; Fiorelli G; Marinoni T; Natali A; Costantini A; Serio M; Martini L
J Clin Endocrinol Metab; 1989 Feb; 68(2):461-8. PubMed ID: 2465302
[TBL] [Abstract][Full Text] [Related]
17. Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer.
van der Sluis TM; Vis AN; van Moorselaar RJ; Bui HN; Blankenstein MA; Meuleman EJ; Heijboer AC
BJU Int; 2012 Jan; 109(2):176-82. PubMed ID: 21992222
[TBL] [Abstract][Full Text] [Related]
18. Glucocorticoids are induced while dihydrotestosterone levels are suppressed in 5-alpha reductase inhibitor treated human benign prostate hyperplasia patients.
Jin R; Forbes C; Miller NL; Strand D; Case T; Cates JM; Kim HH; Wages P; Porter NA; Mantione KM; Burke S; Mohler JL; Matusik RJ
Prostate; 2022 Oct; 82(14):1378-1388. PubMed ID: 35821619
[TBL] [Abstract][Full Text] [Related]
19. Prostate diseases--role of sex steroids and their inhibitors.
Welén K; Damber JE
Best Pract Res Clin Endocrinol Metab; 2011 Apr; 25(2):355-67. PubMed ID: 21397203
[TBL] [Abstract][Full Text] [Related]
20. Intratissular androgens in benign prostatic hyperplasia and prostatic cancer.
Voigt KD; Bartsch W
J Steroid Biochem; 1986 Nov; 25(5B):749-57. PubMed ID: 2433505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]